Icelandic gene database will uphold patients' rights

doi:10.1136/bmj.318.7186.806

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Haraldsdóttir Ragnheidr, Deputy permanent secretary.

Ministry of Health and Social Security, Reykjavik, Iceland

EDITOR—Berger's news story on the Icelandic gene database1 gives an inaccurate and biased account of a complex issue.

The proposed database will not exclude biotechnology companies or pharmaceutical companies from access to data on Icelandic patients, nor are exclusive rights given to one company to develop new drugs or to test candidate drugs. These studies will continue to be allowed as long …